Journal ArticleDOI
Inhibition of cancer cell growth by ruthenium(II) arene complexes
Morris Robert Edward,Rhona E. Aird,Piedad del Socorro Murdoch,Haimei Chen,Jeffrey Cummings,Nathan D. Hughes,Simon Parsons,Andrew Parkin,Gary Boyd,Duncan I. Jodrell,Peter J. Sadler +10 more
Reads0
Chats0
TLDR
These chelated Ru(II) arene complexes have potential as novel metal-based anticancer agents with a mechanism of action different from that of the Ru(III) complex currently on clinical trial.Abstract:
Inhibition of the growth of the human ovarian cancer cell line A2780 by organometallic ruthenium(II) complexes of the type [(eta(6)-arene)Ru(X)(Y)(Z)], where arene is benzene or substituted benzene, X, Y, and Z are halide, acetonitrile, or isonicotinamide, or X,Y is ethylenediamine (en) or N-ethylethylenediamine, has been investigated. The X-ray crystal structures of the complexes [(eta(6)-p-cymene)Ru(en)Cl]PF(6) (5), [(eta(6)-p-cymene)RuCl(2)(isonicotinamide)] (7), and [(eta(6)-biphenyl)Ru(en)Cl]PF(6) (9) are reported. They have "piano stool" geometries with eta(6) coordination of the arene ligand. Complexes with X,Y as a chelated en ligand and Z as a monofunctional leaving group had the highest activity. Complexes 5, 6 (the iodo analogue of 5), 9, and 10 (ethylethylenediamine analogue of 9) were as active as carboplatin. Hydrolysis of the reactive Ru-Cl bond in complex 5 was detected by HPLC but was suppressed by the addition of chloride ions. Complex 5 binds strongly and selectively to G bases on DNA oligonucleotides to form monofunctional adducts. No inhibition of topoisomerase I or II by complexes 5, 6, or 9 was detected. These chelated Ru(II) arene complexes have potential as novel metal-based anticancer agents with a mechanism of action different from that of the Ru(III) complex currently on clinical trial.read more
Citations
More filters
Journal ArticleDOI
New metal complexes as potential therapeutics.
TL;DR: Biological carriers conjugated to cisplatin analogs have improved specificity for tumor tissue, thereby reducing side effects and drug resistance, and metal-based chemotherapeutic compounds have the potential to modulate the biological properties of superoxide anion and nitric oxide.
Journal ArticleDOI
The development of anticancer ruthenium(II) complexes: from single molecule compounds to nanomaterials
TL;DR: This review focuses on the likely mechanisms of action of ruthenium(ii)-based anticancer drugs and the relationship between their chemical structures and biological properties, and highlights the catalytic activity and the photoinduced activation of r Ruthenium (ii) complexes, their targeted delivery, and their activity in nanomaterial systems.
Journal ArticleDOI
In Vitro and in Vivo Evaluation of Ruthenium(II)−Arene PTA Complexes
Claudine Scolaro,Alberta Bergamo,Laura Brescacin,R. Delfino,Moreno Cocchietto,Gábor Laurenczy,Tilmann J. Geldbach,Gianni Sava,Paul J. Dyson +8 more
TL;DR: Results show that these ruthenium(II)-arene complexes can reduce the growth of lung metastases in CBA mice bearing the MCa mammary carcinoma in the absence of a corresponding action at the site of primary tumor growth.
Journal ArticleDOI
Organometallic chemistry, biology and medicine: ruthenium arene anticancer complexes
TL;DR: Initial studies on amino acids and nucleotides suggest that kinetic and thermodynamic control over a wide spectrum of reactions of Ru(II) arene complexes with biomolecules can be achieved.
Journal ArticleDOI
The Medicinal Applications of Imidazolium Carbene Metal Complexes
TL;DR: This review will discuss in detail the medicinal applications of various transition metal-NHC complexes including silver, gold, rhodium, ruthenium, and palladium along with proposed mechanisms of action to suppress the bacterial growth or proliferation of tumor cells will be discussed.
References
More filters
Journal ArticleDOI
Non-platinum chemotherapeutic metallopharmaceuticals.
Journal ArticleDOI
Correlation between cytotoxicity and DNA binding of polypyridyl ruthenium complexes.
TL;DR: The cytotoxicity of chloropolypyridyl ruthenium complexes of structural formulas, and the cytotoxic mer-[Ru(terpy)Cl3] exhibits a significant DNA interstrand cross-linking, point to a potential new class of metal-based antitumor compounds acting by a mechanism involving DNAInterstrandCrosslinking.
Journal ArticleDOI
Binding of ruthenium(III) anti-tumor drugs to human lactoferrin probed by high resolution X-ray crystallographic structure analyses
TL;DR: In this paper, the binding sites of three Ru(III) complexes with anti-tumor activity were investigated by X-ray crystallography in order to gain insights into how such complexes might be carried during transferrin-mediated delivery to cells.
Journal ArticleDOI
Synthesis and structural characterization of η6-arene-ruthenium(II) complexes of α-amino acids with coordinating side chains
William S. Sheldrick,S. Heeb +1 more
TL;DR: In this article, the amino acid ligands are tridentate in 1, with deprotonated sulphur atoms adopting a bridging position between two ruthenium atoms, leading to the formation of a four-membered RuSRuS-ring.